aZhongshan Ophthalmic Center, Sun Yat-sen University, WHO Collaborating Centre for Eye Care and Vision, State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and ...
If you deal with chronic migraines, you’re all too familiar with the debilitating pain, sensitivity to bright lights and queasiness that come with them. But what actually causes migraines in the first ...
A large study spanning more than 40 years suggested that migraines in midlife were associated with a modest increase in the long-term risk of dementia. Adults with migraines in midlife were slightly ...
DEAR DR. ROACH: I read your recent column about migraines and strokes. About 40 years ago, I began having occasional visual-interference episodes with zigzags, blurry central vision, and more that ...
Dear Dr. Roach: I read your recent column about migraines and strokes. About 40 years ago, I began having occasional visual-interference episodes with zigzags, blurry central vision, and more that ...
DEAR DR. ROACH: I read your recent column about migraines and strokes. About 40 years ago, I began having occasional visual-interference episodes with zigzags, blurry central vision, and more that ...
March 20 (Reuters) - EyePoint (EYPT.O), opens new tab filed a lawsuit on Friday accusing rival Ocular Therapeutix (OCUL.O), opens new tab of spreading false or misleading information about EyePoint ...
I’ve had the great thrill of seeing the northern lights, both from Alaska and Iceland. But that experience pales next to what I witnessed recently at my favorite coffee shop. I was there for my usual ...
Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...
Ocular Therapeutix (OCUL) lost ~22% in the premarket on Tuesday after the company released data from a late-stage trial evaluating Axpaxli, its experimental therapy for wet age-related macular ...
Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched position in wet age-related macular degeneration (AMD) with investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results